140 related articles for article (PubMed ID: 31445735)
1. Successful Treatment of a Miliary Metastatic NSCLC Patient With Activating EGFR Exon 20 Insertion Mutation with Response to Poziotinib.
Yang J; Yang J; Ban S; Li X; Chen X; Yang J; Qian J
J Thorac Oncol; 2019 Sep; 14(9):e198-e200. PubMed ID: 31445735
[No Abstract] [Full Text] [Related]
2. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
Prelaj A; Bottiglieri A; Proto C; Lo Russo G; Signorelli D; Ferrara R; Galli G; De Toma A; Viscardi G; Brambilla M; Lobefaro R; Nichetti F; Manglaviti S; Occhipinti M; Labianca A; Ganzinelli M; Gallucci R; Zilembo N; Greco GF; Torri V; de Braud F; Garassino MC
Eur J Cancer; 2021 May; 149():235-248. PubMed ID: 33820681
[TBL] [Abstract][Full Text] [Related]
3. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
[TBL] [Abstract][Full Text] [Related]
4. EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy.
Poonia S; Berge EM; Aisner DL; Damek D; Doebele RC
Clin Lung Cancer; 2014 Sep; 15(5):387-9. PubMed ID: 24894944
[No Abstract] [Full Text] [Related]
5. A Patient with EGFR Exon 20 Insertion-Mutant Non-Small Cell Lung Cancer Responded to Osimertinib plus Cetuximab Combination Therapy.
Fang W; Huang Y; Gan J; Hong S; Zhang L
J Thorac Oncol; 2019 Sep; 14(9):e201-e202. PubMed ID: 31445736
[No Abstract] [Full Text] [Related]
6. Poziotinib in Non-Small-Cell Lung Cancer Harboring
Le X; Cornelissen R; Garassino M; Clarke JM; Tchekmedyian N; Goldman JW; Leu SY; Bhat G; Lebel F; Heymach JV; Socinski MA
J Clin Oncol; 2022 Mar; 40(7):710-718. PubMed ID: 34843401
[TBL] [Abstract][Full Text] [Related]
7. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC.
Baraibar I; Mezquita L; Gil-Bazo I; Planchard D
Crit Rev Oncol Hematol; 2020 Apr; 148():102906. PubMed ID: 32109716
[TBL] [Abstract][Full Text] [Related]
8. Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups.
Zhang Y; Wang Q; Han ZG; Shan L
Asian Pac J Cancer Prev; 2013; 14(5):2879-83. PubMed ID: 23803047
[TBL] [Abstract][Full Text] [Related]
9. Poziotinib for Patients With
Elamin YY; Robichaux JP; Carter BW; Altan M; Gibbons DL; Fossella FV; Lam VK; Patel AB; Negrao MV; Le X; Mott FE; Zhang J; Feng L; Blumenschein G; Tsao AS; Heymach JV
J Clin Oncol; 2022 Mar; 40(7):702-709. PubMed ID: 34550757
[TBL] [Abstract][Full Text] [Related]
10. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
Elamin YY; Robichaux JP; Carter BW; Altan M; Tran H; Gibbons DL; Heeke S; Fossella FV; Lam VK; Le X; Negrao MV; Nilsson MB; Patel A; Vijayan RSK; Cross JB; Zhang J; Byers LA; Lu C; Cascone T; Feng L; Luthra R; San Lucas FA; Mantha G; Routbort M; Blumenschein G; Tsao AS; Heymach JV
Cancer Cell; 2022 Jul; 40(7):754-767.e6. PubMed ID: 35820397
[TBL] [Abstract][Full Text] [Related]
11. Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
Longo L; Mengoli MC; Bertolini F; Bettelli S; Manfredini S; Rossi G
Lung Cancer; 2017 Jan; 103():24-26. PubMed ID: 28024692
[TBL] [Abstract][Full Text] [Related]
12. NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
Dillon B; Naidoo B; Knight H; Clark P
Lancet Oncol; 2012 Aug; 13(8):764-5. PubMed ID: 23024988
[No Abstract] [Full Text] [Related]
13. Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC.
van Kempen LC; Wang H; Aguirre ML; Spatz A; Kasymjanova G; Vilacha JF; Groves MR; Agulnik J; Small D
J Thorac Oncol; 2018 Sep; 13(9):e161-e163. PubMed ID: 29704676
[No Abstract] [Full Text] [Related]
14. [Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer].
Zhou W; Zhang W; Han B
Zhongguo Fei Ai Za Zhi; 2020 Feb; 23(2):118-126. PubMed ID: 32093456
[TBL] [Abstract][Full Text] [Related]
15. The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.
Watanabe M; Oizumi S; Kiuchi S; Yamada N; Yokouchi H; Fukumoto S; Harada M
Intern Med; 2018 Apr; 57(7):993-996. PubMed ID: 29225262
[TBL] [Abstract][Full Text] [Related]
16. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
[TBL] [Abstract][Full Text] [Related]
17. Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal?
Borm FJ; Smit EF
J Thorac Oncol; 2023 Aug; 18(8):964-966. PubMed ID: 37479324
[No Abstract] [Full Text] [Related]
18. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F
Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
[TBL] [Abstract][Full Text] [Related]
19. A Case of Primary Resistance to Gefitinib due to Novel Deletion-Insertion Mutation of EGFR Exon 19 in NSCLC.
Xia P; Liu E; Li P; Li W; Jiang G
J Thorac Oncol; 2019 Jun; 14(6):e117-e119. PubMed ID: 31122561
[No Abstract] [Full Text] [Related]
20. A Patient of Advanced NSCLC with a New EGFR Exon 19 Insertion Mutation and its Response to EGFR-TKIs.
Zhu N; Dong C; Weng S; Yuan Y; Yuan Y
J Coll Physicians Surg Pak; 2019 Dec; 29(12):S126-S128. PubMed ID: 31779765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
